BACKGROUND The EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study demonstrated that patients with multiple sclerosis (MS) who initiate interferon beta-1a therapy with 44 microg 3 times weekly (TIW) were less likely to have a relapse or activity on magnetic resonance imaging (MRI) compared with those who initiate therapy at a dosage of 30 microg 1...

Type I interferons are implicated in the pathogenesis of systemic lupus erythematosus (SLE). Type I interferon-inducible mRNAs are widely and concordantly overexpressed in the periphery and involved tissues of a subset of SLE patients, and provide utility as pharmacodynamic biomarkers to aid dose selection, as well as potential indicators of patients who might respond favorably to anti-IFNα the...

BACKGROUND High dose interferon induction treatment of hepatitis C viral infection blocks viral production over 95%. Since dose reduction is often performed due to clinical considerations, the effect of dose reduction on hepatitis C virus kinetics was studied. METHODS A new model that allowed longitudinal changes in the parameters of viral dynamics was used in a group of genotype-1 patients (...

Adjuvant therapy for patients with melanoma using interferon remains controversial despite numerous randomized clinical trials. There can be no doubt that interferon works—that is, it has biologic activity sufficient to alter the natural history of resected melanoma. Multiple randomized trials have demonstrated that adjuvant interferon prolongs recurrence free survival compared with observation...

BACKGROUND The optimal treatment for hepatitis C patients unresponsive to interferon is unclear. High-dose induction interferon may enhance early viral clearance, whilst ribavirin reduces relapse; in combination, they may improve sustained virological response rates. AIM To compare the efficacy and safety of re-treatment with interferon induction, with or without ribavirin, in interferon non-...

conclusions more than one-quarter of treatment-experienced patients with hcv genotype 3 achieved svr after re-treatment with consensus interferon plus ribavirin. objectives we aimed to assess the efficacy and safety of cifn and ribavirin in non-responders and relapsers to pegylated interferon with ribavirin therapy. patients and methods this open-label investigator-initiated study included 44 p...

AIMS AND BACKGROUND Glioblastoma has a poor prognosis, with few therapeutic options if it recurs. We report a case in which we were able to inhibit the growth of a recurrent glioblastoma by weekly single-dose administration of interferon-beta. CASE REPORT A patient with recurrent glioblastoma after radiation and chemotherapy was treated with nimustine and interferon-beta. After 2 cycles of ni...

Interferons (IFN) have antiviral activity against many viruses, including SARS-CoV-2. A combination of IFN-a2b and the antioxidant taurine is widely used in Russian Federation, its has not been studied before. The aim this study was to determine interferon drugs, with without it. included cytotoxicity assays preparations, when stored according instructions at 2–8°C, after 1 month storage temper...

Cardiac arrhythmias and syncope are rare consequence of therapy with pegylated interferon. We report a 55-year-old Egyptian woman who developed palpitation and syncopal attacks twice within 3 months after starting therapy with pegylated interferon alpha2b and ribavirin for the treatment of chronic hepatitis C virus. Hepatitis C virus-RNA was undetectable after 12 week. The electrocardiogram hol...